News › GlobeNewswire Inc.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

GlobeNewswire Inc. • Dec 26, 2025 10:55am (New York) •By Faruqi & Faruqi, Llp

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

A federal securities class action has been filed against Telix Pharmaceuticals for allegedly making false and misleading statements about its prostate cancer therapeutic candidates and supply chain quality. The company received an SEC subpoena in July 2025 and an FDA Complete Response Letter in August 2025 citing manufacturing deficiencies, resulting in significant stock price declines of 13% and 21% respectively. Investors who purchased securities between February 21 and August 28, 2025 are encouraged to contact the law firm by the January 9, 2026 deadline to seek lead plaintiff status.

← Back to news Read Original Article

Insights

XOM neutral

Mentioned as industry peer with strong dividend history, but not primary focus of recommendation

TLX negative

The company faces federal securities litigation alleging material misstatements about drug development progress and supply chain quality. SEC subpoena and FDA rejection of a key product application citing manufacturing deficiencies resulted in significant stock price declines (13-21%), indicating serious regulatory and operational challenges.

Keywords

#securities fraud #class action lawsuit #prostate cancer therapeutics #FDA Complete Response Letter #manufacturing deficiencies #SEC investigation #investor losses

Tickers

TLX

← Prev: SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Firefly

Next: PRMB Investors Have Opportunity to Lead Primo Brands Corporation Securities Fraud Lawsuit with the Schall Law Firm →